Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2021.06

  -

  Now

  Sapporo Medical University   School of Medicine   講師

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Gastroenterology  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• LINC02154 promotes cell cycle and mitochondrial function in oral squamous cell carcinoma.

  Takeshi Niinuma, Hiroshi Kitajima, Tatsuya Sato, Toshifumi Ogawa, Kazuya Ishiguro, Masahiro Kai, Eiichiro Yamamoto, Yui Hatanaka, Iyori Nojima, Mutsumi Toyota, Akira Yorozu, Shohei Sekiguchi, Noritsugu Tohse, Masato Furuhashi, Hiroshi Ohguro, Akihiro Miyazaki, Hiromu Suzuki

  Cancer science    2024.11  [International journal]

  　View Summary

  Long noncoding RNAs (lncRNAs) play pivotal roles in the development of human malignancies, though their involvement in oral squamous cell carcinoma (OSCC) remains incompletely understood. Using The Cancer Genome Atlas (TCGA) dataset, we analyzed expression of 7840 lncRNAs in primary head and neck squamous cell carcinoma (HNSCC) and found that upregulation of LINC02154 is associated with a poorer prognosis. LINC02154 knockdown in OSCC cell lines induced cell cycle arrest and apoptosis, and significantly attenuated tumor growth in vitro and in vivo. Notably, depletion of LINC02154 downregulated FOXM1, a master regulator of cell cycle-related genes. RNA pulldown and mass spectrometry analyses identified a series of proteins that could potentially interact with LINC02154, including HNRNPK and LRPPRC. HNRNPK stabilizes FOXM1 expression by interacting with the 3'-UTR of FOXM1 mRNA, which suggests LINC02154 and HNRNPK promote cell cycling by regulating FOXM1 expression. Additionally, LINC02154 positively regulates HNRNPK expression by inhibiting microRNAs targeting HNRPNK. Moreover, LINC02154 affects mitochondrial function by interacting with LRPPRC. Depletion of LINC02154 suppressed expression of mitochondrial genes, including MTCO1 and MTCO2, and inhibited mitochondrial respiratory function in OSCC cells. These results suggest that LINC02154 exerts its oncogenic effects by modulating the cell cycle and oxidative phosphorylation in OSCC, highlighting LINC02154 as a potential therapeutic target.

  DOI PubMed

• AEBP1 is a negative regulator of skeletal muscle cell differentiation in oral squamous cell carcinoma.

  Fumika Okazaki, Akira Yorozu, Shohei Sekiguchi, Takeshi Niinuma, Reo Maruyama, Hiroshi Kitajima, Eiichiro Yamamoto, Kazuya Ishiguro, Mutsumi Toyota, Yui Hatanaka, Koyo Nishiyama, Kazuhiro Ogi, Masahiro Kai, Kenichi Takano, Shingo Ichimiya, Akihiro Miyazaki, Hiromu Suzuki

  Scientific reports   14 ( 1 ) 27425 - 27425  2024.11  [International journal]

  　View Summary

  The tumor microenvironment plays a pivotal role in cancer development. We recently reported that in oral squamous cell carcinoma (OSCC), adipocyte enhancer-binding protein 1 (AEBP1) is abundantly expressed in cancer-associated fibroblasts (CAFs), leading to CAF activation and inhibition of CD8 + T cell infiltration. In the present study, we investigated whether AEBP1 contributes to the destruction and atrophy of muscle tissues in OSCC. By analyzing human skeletal muscle myoblasts (HSMMs), we found that AEBP1 is downregulated during muscle cell differentiation. Transcriptome analysis revealed that AEBP1 knockdown significantly upregulates myogenesis-related genes in HSMMs, and qRT-PCR and western blot analyses confirmed the induction of muscle-related genes, including MYOG, in HSMMs after AEBP1 knockdown. Conversely, ectopic expression of AEBP1 strongly suppressed myogenesis-related genes in HSMMs. Notably, indirect co-culture of HSMMs with OSCC cells led to AEBP1 upregulation and robust suppression of muscle-related genes in HSMMs. Treatment with TGF-β1 also upregulated AEBP1 and suppressed expression of muscle-related genes in HSMMs. Our findings suggest that AEBP1 is a negative regulator of skeletal muscle cell differentiation and that OSCC cells inhibit muscle cell differentiation, at least in part, by inducing AEBP1.

  DOI PubMed

• Downregulation of SMOC1 is associated with progression of colorectal traditional serrated adenomas.

  Hironori Aoki, Akira Takasawa, Eiichiro Yamamoto, Takeshi Niinuma, Hiro-O Yamano, Taku Harada, Toshiyuki Kubo, Akira Yorozu, Hiroshi Kitajima, Kazuya Ishiguro, Masahiro Kai, Akio Katanuma, Toshiya Shinohara, Hiroshi Nakase, Tamotsu Sugai, Makoto Osanai, Hiromu Suzuki

  BMC gastroenterology   24 ( 1 ) 91 - 91  2024.03  [International journal]

  　View Summary

  BACKGROUND: Aberrant DNA methylation is prevalent in colorectal serrated lesions. We previously reported that the CpG island of SMOC1 is frequently methylated in traditional serrated adenomas (TSAs) and colorectal cancers (CRCs) but is rarely methylated in sessile serrated lesions (SSLs). In the present study, we aimed to further characterize the expression of SMOC1 in early colorectal lesions. METHODS: SMOC1 expression was analyzed immunohistochemically in a series of colorectal tumors (n = 199) and adjacent normal colonic tissues (n = 112). RESULTS: SMOC1 was abundantly expressed in normal colon and SSLs while it was significantly downregulated in TSAs, advanced adenomas and cancers. Mean immunohistochemistry scores were as follows: normal colon, 24.2; hyperplastic polyp (HP), 18.9; SSL, 23.8; SSL with dysplasia (SSLD)/SSL with early invasive cancer (EIC), 15.8; TSA, 5.4; TSA with high grade dysplasia (HGD)/EIC, 4.7; non-advanced adenoma, 21.4; advanced adenoma, 11.9; EIC, 10.9. Higher levels SMOC1 expression correlated positively with proximal colon locations and flat tumoral morphology, reflecting its abundant expression in SSLs. Among TSAs that contained both flat and protruding components, levels of SMOC1 expression were significantly lower in the protruding components. CONCLUSION: Our results suggest that reduced expression of SMOC1 is associated with progression of TSAs and conventional adenomas and that SMOC1 expression may be a biomarker for diagnosis of serrated lesions and risk prediction in colorectal tumors.

  DOI PubMed

• ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma.

  Shohei Sekiguchi, Akira Yorozu, Fumika Okazaki, Takeshi Niinuma, Akira Takasawa, Eiichiro Yamamoto, Hiroshi Kitajima, Toshiyuki Kubo, Yui Hatanaka, Koyo Nishiyama, Kazuhiro Ogi, Hironari Dehari, Atsushi Kondo, Makoto Kurose, Kazufumi Obata, Akito Kakiuchi, Masahiro Kai, Yoshihiko Hirohashi, Toshihiko Torigoe, Takashi Kojima, Makoto Osanai, Kenichi Takano, Akihiro Miyazaki, Hiromu Suzuki

  Cancers   15 ( 17 )  2023.08  [International journal]

  　View Summary

  We previously showed that upregulation of adipocyte enhancer-binding protein 1 (AEBP1) in vascular endothelial cells promotes tumor angiogenesis. In the present study, we aimed to clarify the role of stromal AEBP1/ACLP expression in oral squamous cell carcinoma (OSCC). Immunohistochemical analysis showed that ACLP is abundantly expressed in cancer-associated fibroblasts (CAFs) in primary OSCC tissues and that upregulated expression of ACLP is associated with disease progression. Analysis using CAFs obtained from surgically resected OSCCs showed that the expression of AEBP1/ACLP in CAFs is upregulated by co-culture with OSCC cells or treatment with TGF-β1, suggesting cancer-cell-derived TGF-β1 induces AEBP1/ACLP in CAFs. Collagen gel contraction assays showed that ACLP contributes to the activation of CAFs. In addition, CAF-derived ACLP promotes migration, invasion, and in vivo tumor formation by OSCC cells. Notably, tumor stromal ACLP expression correlated positively with collagen expression and correlated inversely with CD8+ T cell infiltration into primary OSCC tumors. Boyden chamber assays suggested that ACLP in CAFs may attenuate CD8+ T cell migration. Our results suggest that stromal ACLP contributes to the development of OSCCs, and that ACLP is a potential therapeutic target.

  DOI PubMed

• TM4SF1-AS1 inhibits apoptosis by promoting stress granule formation in cancer cells

  Hiroshi Kitajima, Reo Maruyama, Takeshi Niinuma, Eiichiro Yamamoto, Akira Takasawa, Kumi Takasawa, Kazuya Ishiguro, Akihiro Tsuyada, Ryo Suzuki, Gota Sudo, Toshiyuki Kubo, Kei Mitsuhashi, Masashi Idogawa, Shoichiro Tange, Mutsumi Toyota, Ayano Yoshido, Kohei Kumegawa, Masahiro Kai, Kazuyoshi Yanagihara, Takashi Tokino, Makoto Osanai, Hiroshi Nakase, Hiromu Suzuki

  Cell Death & Disease ( Springer Science and Business Media LLC )  14 ( 7 )  2023.07

  　View Summary

  Abstract Long noncoding RNAs (lncRNAs) play pivotal roles in tumor development. To identify dysregulated lncRNAs in gastric cancer (GC), we analyzed genome-wide trimethylation of histone H3 lysine 4 (H3K4me3) to screen for transcriptionally active lncRNA genes in the non-tumorous gastric mucosa of patients with GC and healthy individuals. We found that H3K4me3 at TM4SF1-AS1 was specifically upregulated in GC patients and that the expression of TM4SF1-AS1 was significantly elevated in primary and cultured GC cells. TM4SF1-AS1 contributes to GC cell growth in vitro and in vivo, and its oncogenic function is mediated, at least in part, through interactions with purine-rich element-binding protein α (Pur-α) and Y-box binding protein 1 (YB-1). TM4SF1-AS1 also activates interferon signaling in GC cells, which is dependent on Pur-α and RIG-I. Chromatin isolation by RNA purification (ChIRP)-mass spectrometry demonstrated that TM4SF1-AS1 was associated with several stress granule (SG)-related proteins, including G3BP2, RACK1, and DDX3. Notably, TM4SF1-AS1 promoted SG formation and inhibited apoptosis in GC cells by sequestering RACK1, an activator of the stress-responsive MAPK pathway, within SGs. TM4SF1-AS1-induced SG formation and apoptosis inhibition are dependent on Pur-α and YB-1. These findings suggested that TM4SF1-AS1 contributes to tumorigenesis by enhancing SG-mediated stress adaptation.

  DOI

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• Analysis of AEBP1 in the microenvironment of head and neck squamous cell carcinoma

  Shohei Sekiguchi, Akira Yorozu, Eiichiro Yamamoto, Takeshi Niinuma, Akira Takasawa, Gota Sudo, Kazushige Koike, Yui Hatanaka, Ayano Yoshido, Hiroshi Kitajima, Masahiro Kai, Makoto Osanai, Kenichi Takano, Akihiro Miyazaki, Hiromu Suzuki

  CANCER SCIENCE ( WILEY )  113   1506 - 1506  2022.02

  Research paper, summary (international conference)  

• LOW EXPRESSION OF miRNA-199-5p AND miRNA-374 CAN PREDICT THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B AFTER ADMINISTRATION OF NUCLEOSIDE ANALOG.

  Hideaki Takahashi, Chiaki Okuse, Norie Yamada, Takeshi Niinuma, Masahiro Kai, Hideki Wakasugi, Noriyuki Akutsu, Hiroshi Yotsuyanagi, Michihiro Suzuki, Hiromu Suzuki, Fumio Itoh

  HEPATOLOGY ( WILEY )  74   656A - 657A  2021.10

  Research paper, summary (international conference)  

• SALL3のエピゲノム異常はトリプルネガティブ乳癌の薬剤抵抗性の一因となる

  松下 洋輔, 小松 正人, 清谷 一馬, 新沼 猛, 鈴木 拓, 吉丸 哲郎, 田嶋 敦, 井本 逸勢, 本田 純子, 古川 洋一, 中村 祐輔, 三好 康雄, 笹 三徳, 片桐 豊雅

  日本癌学会総会記事 ( (一社)日本癌学会 )  80回   [J14 - 3]  2021.09

• SMOC1の大腸腫瘍診断マーカーとしての臨床的有用性の検討

  青木 敬則, 山本 英一郎, 高澤 啓, 新沼 猛, 山野 泰穂, 萬 顕, 北嶋 洋志, 甲斐 正広, 小山内 誠, 仲瀬 裕志, 菅井 有, 鈴木 拓

  日本癌学会総会記事 ( (一社)日本癌学会 )  80回   [P14 - 4]  2021.09

• SMOC1の大腸腫瘍診断マーカーとしての臨床的有用性の検討

  青木 敬則, 山本 英一郎, 高澤 啓, 新沼 猛, 山野 泰穂, 萬 顕, 北嶋 洋志, 甲斐 正広, 小山内 誠, 仲瀬 裕志, 菅井 有, 鈴木 拓

  日本癌学会総会記事 ( (一社)日本癌学会 )  79回   PJ14 - 1  2020.10

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• Identification of colorectal cancer-associated microproteins translated from noncoding RNAs

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2024.04

  -

  2027.03

   

  北嶋 洋志, 高澤 啓, 新沼 猛

• 大腸低分化腺がんにおけるSAA1の分子機能解明と診断・治療への応用

  基盤研究(C)

  Project Year :

  2022.04

  -

  2025.03

   

  青木 敬則, 高澤 啓, 山本 英一郎, 新沼 猛

• DOT1L阻害によるインターフェロン応答の機序解明とがん免疫療法への応用

  基盤研究(B)

  Project Year :

  2022.04

  -

  2025.03

   

  鈴木 拓, 仲瀬 裕志, 新沼 猛, 北嶋 洋志

• がん細胞のインターフェロンシグナルを制御する長鎖noncoding RNAの解析

  基盤研究(C)

  Project Year :

  2021.04

  -

  2024.03

   

  新沼 猛, 鈴木 拓

  　View Summary

  消化器癌におけるDLEU1の機能解析を行うために大腸癌細胞株RKO、HCT116、DLD1、SW480を用いてDLEU1をノックダウンし細胞増殖に与える影響についてCCK-8を用いたcell viability assayを行った。大腸癌についてはいずれの細胞株においてもDLEU1のノックダウンは細胞増殖を抑制した。DLEU1のノックダウンがIFNシグナルに与える影響を調べるためにDLD1、SW480においてIFITM1、IFITM3の発現をRT-qPCRにて解析したところ、口腔扁平上皮癌と異なり、これらのISGｓは発現が不変～上昇傾向であった。HCT116においてはDLEU1のノックダウンによりIFITM1は発現低下、IFITM3は発現上昇、RKOにおいてはIFITM1は発現低下が認められた。DLD1、SW480ではIFITM1、IFITM3ともDLEU1のノックダウンにより発現が上昇傾向であった。さらに他の消化器癌においてDLEU1の機能を解析するために食道癌細胞株であるTE5、TE9、TE15を用いてDLEU1をノックダウンし、細胞増殖に与える影響についてcell viability assayを行った。異なるsiRNAを用いて解析したが、食道癌においてはDLEU1のノックダウンにより増殖の亢進、抑制いずれも起こり一定の傾向が認められなかった。ISGｓに与える影響についてもRT-qPCRによりIFITM3、IFITM1の発現も解析したが、発現の上昇・低下いずれも認められ一定の傾向を示さなかった。TE-5においてはIFITM1、IFITM3は発現が低下傾向であったが、TE-9においてはIFITM3は発現が上昇、TE-15はIFITM1の発現が低下傾向であった。

• Comprehensive analysis of epigenetic alteration and lncRNA involved to colon cancer development

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2018.04

  -

  2021.03

   

  Niinuma Takeshi

  　View Summary

  In this study, we analyzed the expression of lncRNA in gastrointestinal tumors by using publicly available TCGA database and compared that in normal tissues or tumors. We tested several methods to select the prospective lncRNA genes and analyzed the function of selected lncRNAs. Among them, we assessed the function of lncX gene. Depletion of lncX by using specific siRNA reduced cell viability and induced apoptosis in several cancer cells. To investigate the effects on gene expression profiles by knockdown of lncX, we performed gene expression microarray analysis. Accordingly, we found that a number of genes regulating cell cycle were significantly downregulated. We confirmed the reduction of AURKA, cyclin B1, and survivin. Then, we performed luciferase reporter assay by using promoter of AURKA gene. We assessed the effects of lncX with WT CED or Mut CED reporter. Consequently, results of reporter assay suggest that lncX is involve to the activation of cell cycle genes.

display all >>